Abstract
Rationale: Metabolic effects of sodium-dependent glucose co-transporter 2 (SGLT2i) have not been fully described and there is a discrepancy on some clinical results related to this drug. Our main aim was to detect if there are some predictor factors to identify what patients would have higher weight loss response to dapagliflozin focusing on whether intensity of glycosuria correlates to the intensity of metabolic and anthropometic changes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
